IP Library Granted Patent US 9,522,107
Granted Patent B2
US 9,522,107 · App. 14/876,778 · Granted Dec 20, 2016

Stable silk protein fragment compositions

Inventors: Gregory H. Altman (Arlington, MA); Rebecca L. Horan (Arlington, MA); Rachel Lee Dow (Medford, MA); Rachel M. Lind (Somers, NY); Dylan S. Haas (Yorktown Heights, NY)
Assignee: Silk Therapeutics, Inc.
A61K8/64A45D33/00A61K8/02A61K8/0216A61K8/042A61K8/19A61K8/27A61K8/29A61K8/365A61K8/4953A61K8/676A61K8/735A61K8/922A61K8/97A61K9/08A61K38/00A61K38/012A61Q17/04A61Q19/00A61Q19/007A61Q19/02A61Q19/08C07K1/12C07K14/43586A61K8/987A61K2800/591A61K2800/72A61K2800/74A61K2800/75
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,522,107
App. No.
14/876,778
Granted
Dec 20, 2016
Kind
B2
Abstract

A composition is disclosed that includes pure silk fibroin-based protein fragments that are substantially devoid of sericin, wherein the composition has an average weight average molecular weight ranging from about 17 kDa to about 38 kDa, wherein the composition has a polydispersity of between about 1.5 and about 3.0, wherein the composition is substantially homogeneous, wherein the composition between 0 ppm to about 500 ppm of inorganic residuals, and wherein the composition includes between 0 ppm to about 500 ppm of organic residuals.

Claims (19)

1. A composition comprising:

pure silk fibroin-based protein fragments having about 0.01% (w/w) to about 10% (w/w) sericin, wherein the fragments have an average weight average molecular weight ranging from about 35 kDa to about 40 kDa, wherein the fragments have a polydispersity of from about 1.5 to about 3.0,

wherein the composition is substantially homogeneous,

wherein the composition includes between 0 ppm to 500 ppm of inorganic residuals,

where-in the composition includes between 0 ppm to 500 ppm of organic residuals, and

wherein the composition does not spontaneously or gradually gelate and does not visibly change in color or turbidity when in a solution for at least 10 days.

2. The composition of claim 1 wherein the inorganic residuals include lithium bromide and wherein the organic residuals include sodium carbonate.

3. The composition of claim 2 wherein the lithium bromide residuals are measurable using a high-performance liquid chromatography lithium bromide assay, and the sodium carbonate residuals are measurable using a high-performance liquid chromatography sodium carbonate assay.

4. The composition of claim 1 wherein the solution is an aqueous solution.

5. The composition of claim 1 in a sealed container.

6. The composition of claim 1 further comprising polyanhydrides.

7. The composition of claim 6 further comprising vitamin C or a derivative thereof.

8. The composition of claim 6 further comprising an alpha hydroxy acid selected from the group consisting of glycolic acid, lactic acid, tartaric acid and citric acid.

9. The composition of claim 6 further comprising hyaluronic acid or its salt form at a concentration of about 0.5 wt. % to about 10.0 wt. %.

10. The composition of claim 6 further comprising at least one of zinc oxide or titanium dioxide.

11. The composition of claim 1 wherein the pure silk fibroin-based protein fragments are hypoallergenic.

12. The composition of claim 1 having less than 10 colony forming units per gram.

13. The composition of claim 1 , wherein the composition does not spontaneously or gradually gelate and does not visibly change in color or turbidity when in a solution for at least 30 days.

14. The composition of claim 1 wherein the average weight average molecular weight range and the polydispersity are measurable using a high-performance liquid chromatography assay.

Assignments (5)
CHANGE OF NAME Recorded Feb 25, 2019
From: SILK, INC.
To: EVOLVED BY NATURE, INC.
Reel/Frame 048423/0276 →
CHANGE OF NAME Recorded Feb 21, 2019
From: SILK THERAPEUTICS, INC.
To: SILK, INC.
Reel/Frame 048407/0364 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2019
From: ALTMAN, GREGORY H.
To: SILK THERAPEUTICS, INC.
Reel/Frame 048371/0301 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2019
From: ALTMAN, GREGORY H.; HORAN, REBECCA L.; DOW, RACHEL LEE; HASS, DYLAN S.; LIND, RACHEL M.
To: SILK THERAPEUTICS, INC.
Reel/Frame 048372/0133 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 19, 2019
From: ALTMAN, GREGORY H.; HORAN, REBECCA L.; DOW, RACHEL LEE; HASS, DYLAN S.; LIND, RACHEL M.
To: SILK THERAPEUTICS, INC.
Reel/Frame 048372/0232 →
Continuity (5)
Continuation 14503021 · Sep 30, 2014
Provisional Application 61884820 · Sep 30, 2013
Provisional Application 62000928 · May 20, 2014
Provisional Application 62036450 · Aug 12, 2014
Related Publication 20160193130A1 · Jul 7, 2016